LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.
LSUHS leadership, faculty, staff, students and community supporters recently honored the continued growth of research initiatives and funding at the second annual Research Celebration event held on February 25, 2020.
Cherie-Ann O. Nathan, MD is the lead author of a study that found a targeted therapy drug used for breast and kidney cancers may also extend survival for patients with advanced head and neck cancer.
Internationally recognized for his research on inflammatory vascular pathology, specifically on and the relationship between inflammation and vascular growth and function, Dr. Kevil discovered detailed mechanistic relationships between angiogenesis and inflammation.
LISTING OF ALL THE NEWS FROM RESEARCH THROUGHOUT THE INSTITUTION:
Three Fellows in the Department of Pathology and the Center for Cardiovascular Diseases and Sciences have been awarded Fellowships funding their ongoing research into cardiovascular diseases.
Aphios Granted U.S. Patent for Oral Administration of Bryostatin-1 Nanoparticles for Treatment of Neurodegenerative Diseases, which was co-invented by LSU Health Shreveport professor, Dr. J. Steven Alexander.
JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD), TV1001SR, which was invented by LSU Health Shreveport professor and vice chancellor for research, Dr. Chris Kevil.
The Medical Student Research Program provides medical students with the opportunity to gain additional experience in research.
Praveen K. Jaiswal, PhD, a postdoctoral fellow in the Department of Biochemistry and Molecular Biology has received a prestigious Research Scholar Award for Mentored Prostate Cancer Research from the AUA Urology Care Foundation.
Life Savers 2019 is held in honor of Anne Higdon, and proceeds will support cancer education and research grants in Shreveport.
Research and Industry Day (RAID) was hosted at LSU Health Shreveport on October 11.
Scientists have identified a key gene - eIF4G1 - that shows grade and stage specific upregulation in prostate cancer and is overexpressed and/or amplified in the majority of cases of CRPC.
Dr. Samant’s award will support his work on developing esophageal stents and advancing them for future use in a clinical setting.
The CURIOUS summer research program is designed to provide an educational and hands-on research opportunity for underrepresented undergraduate students interested in pursuing research as part of their career goals.
Drs. Kevil and Orr interviewed by American Heart Association News and featured in Washington Post article.
Although frequently overshadowed by the opioid epidemic, surging methamphetamine use nationally and around the world has fueled a chilling crisis of its own, according to a new report;
Rodney Shackelford, DO, PhD, Assistant Professor of Pathology, has been awarded a $40,000 grant from the A-T Children’s Project for his research project titled, “Pharmacologic Correction of the Cellular Sulfide Pool as a Treatment for Ataxia-Telangiectasia.”
A study performed by LSUHS Orthopaedic Surgery faculty, residents and medical students was recently published in and featured on the cover of the Orthopaedic Research Society's Journal of Orthopaedic Research.
LSU Health Shreveport researchers recently presented preliminary findings at the American Heart Association’s Basic Cardiovascular Sciences 2019 Scientific Sessions that use of the illegal stimulant methamphetamine causes build-up of tough protein fibers in heart muscle, which may help explain the development of enlarged hearts and heart failure in users.
40 high school and undergraduate students recently shared the research projects they have spent eight weeks working on in summer programs held at LSU Health Shreveport.
Christopher Pattillo, PhD, Associate Professor of Molecular and Cellular Physiology, has received a grant from the National Heart, Lung, and Blood Institute of the NIH for his five-year project, “Cellular Reductive State Regulates Arteriogenesis.”
A paper authored by many researchers at LSU Health Shreveport on the prevention and treatment of stroke was recently published in Circulation, a journal of the American Heart Association.
Landmark trial looking for potential candidates
LSU Health Shreveport professor Dr. Yuping Wang trained lab staff and her patented research techniques will be utilized in their work.
The goal by Md. Shenuarin Bhuiyan, PhD, is to discover a novel lipid metabolism pathway regulated by Sigmar1 and identify a therapeutic target to prevent lipid abnormalities in obesity, expected to help reverse the impact of obesity on cardiovascular disease risk.
The Louisiana Board of Regents unanimously approved the continuation of the Center for Cardiovascular Diseases and Sciences (CCDS) as a Center of Excellence of research and innovation.
Since July 1, 2018, 17 new research grants have been awarded to LSU Health Shreveport researchers, totaling more than $14 million dollars in funding.
Four trainees in the Center for Cardiovascular Diseases and Sciences at LSU Health Shreveport recently received American Heart Association Fellowships to fund their Pre-doctoral and Post-doctoral Training.
Yufeng Dong, MD, PhD, Assistant Professor of Orthopaedic Surgery, has received an R01 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH for his five-year project studying the treatment of bone loss and bone injuries with modified tissue stem cells.
The grant entitled, “The role of alpha-synuclein in Snx3-retromer mediated recycling of membrane proteins.” provides Dr. Witt with $100,000 per year each year for three years.
Kenneth E. McMartin, PhD, Professor of Pharmacology, Toxicology & Neuroscience, received the American Academy of Clinical Toxicology Distinguished Service Award at the North American Congress of Clinical Toxicology.
The LSU Health Shreveport Department of Molecular & Cellular Physiology and Aphios Corporation have obtained United States Patent No. 9,994,585 entitled “Transplantation Therapies,” for marine pharmaceutical ‘Bryostatin-1,’ which will be used as an additive to organ transport and storage solutions.
Congratulations to Principal Investigator Dr. David Gross for being awarded an R15 AREA grant entitled, “Chromosomal Conformation and Nuclear Organization of Heat Shock Protein Genes.” The grant provides Dr. Gross with $100,000 per year each year for three years.
Almost all deaths from prostate cancer are a result of emergence of CRPC. Scientists from our Department of Biochemistry and Molecular Biology and Feist Weiller Cancer Center have identified a key gene - eIF4G1- that is overexpressed in the majority of cases of CRPC, allowing these cancer cells to rapidly respond to androgen deprivation therapies.